Copyright
©The Author(s) 2015.
World J Respirol. Mar 28, 2015; 5(1): 17-27
Published online Mar 28, 2015. doi: 10.5320/wjr.v5.i1.17
Published online Mar 28, 2015. doi: 10.5320/wjr.v5.i1.17
Type 1 full attended polysomnography | Type 2 full unattended polysomnography | Type 3 limited channels devices | Type 4 continuous single or dual bioparameter recording | |
Number of channels | Minimum 7 | Minimum 7 | Minimum 4 | Minimum of 1 |
Parameters | EEG, EOG, chin EMG, ECG, airflow, respiratory effort, oxygen saturation | EEG, EOG, chin EMG, ECG, airflow, respiratory effort, oxygen saturation | Ventilation (at least two channels of respiratory movement or respiratory movement and airflow), heart rate or ECG, oxygen saturation | Usually oxygen saturation and/or airflow |
Body position | Documented or objectively measured | May be objectively measured | May be objectively measured | Not measured |
Leg movement | EMG or motion sensor desirable | EMG or motion sensor desirable | May be recorded | Not recorded |
Personnel | In constant attendance | Not in attendance | Not in attendance | Not in attendance |
Sleep | Cardiovascular | Oximetry | Position | Effort | Respiratory |
S1-3 EEG channels1 + EOG + chin EMG | C1-More than 1 ECG lead | O1-Oximetry (ear or finger) with recommended sampling2 | P1-Video or visual position measurement | E1-Two RIP belts | R1-Nasal pressure and thermal device |
S2-Less than 3 EEG channels with/without EOG or chin EMG | C2-Peripheral arterial tonometry | O1x-Oximetry (ear or finger) without recommended sampling | P2-Nonvisual position measurement | E2-One RIP belt | R2-Nasal pressure |
S3-Sleep surrogate: e.g., actigraphy | C3-Standard ECG measure (one lead) | O2-Oximetry with alternative site | E3-Derived effort | R3-Thermal device | |
S4-Other sleep measure | C4-Derived pulse | O3-Other oximetry | E4-Other effort measures | R4-End-tidal CO2 | |
C5-other cardiac measures | R5-Other respiratory measures |
Ref. | Year | Population | Sample size | Device | Protocol |
Morales et al[24] | 2012 | Elderly mean age 71.4 yr | 452 | Rescare AutosetTM (ResMed, Sydney, Australia) | PM at home PSG at sleep lab |
Polese et al[22] | 2013 | Elderly > 65 yr | 43 | Stardust II® (Phillips Respironics, Inc., Murrysville, PA, United States) | PM home PM + PSG at sleep lab |
Goodwin et al[31] | 2001 | Children 5 to 12 yr | 157 | Compumedics PS-2 System (Abbotsford, Victoria, Australia) | PM at home |
Zucconi et al[32] | 2003 | Children 3 to 6 yr | 12 | POLY-MESAM; MAP; Martinsried, Germany | PSG at sleep lab PM at sleep lab |
Poels et al[30] | 2003 | Children 2 to 7 yr | 24 | Embletta PDS; Flaga hf Medical Devices, Reykjavik, Iceland) | PM at home |
Rosen et al[35] | 2003 | Children 8 to 11 yr | 55 | PT-2 System SensorMedics, Yorba Linda, California, United States | PM home PSG lab |
Alvarez et al[34] | 2008 | Children 2 to 14 yr | 53 | Edentec Monitoring System (Edentrace II, Model 3711; Edentec Corporation, Nellcor Puritan Bennett, Eden Prairie, Minnesota, United States) | PSG + PM at sleep lab |
Sardón Prado et al[37] (abstract) | 2006 | Children | 132 | Not informed | PM at hospital PM at home |
Amorim et al[38] (abstract) | 2004 | Children Mean age 10.6 yr | 31 | Not informed | PM at home |
Quintana-Gallego et al[50] | 2004 | Heart failure LVEF ≤ 45% | 75 | Apnoescreen II; Erich Jaeger Gmbh and CoKg, Wuerzburg, Germany | PSG at sleep lab PM at home |
Abraham et al[51] | 2006 | Heart failure LVEF ≤ 35% | 50 | ClearPath System Nx-301; Nexan Inc, Alpharetta, GA | PSG + PM at sleep lab PM at home |
Smith et al[52] | 2007 | Heart failure LVEF ≤ 45% | 20 | Embletta; Flaga, Iceland | PSG + PM at sleep lab PM at home |
Takama et al[57] | 2010 | CAD patients | 83 | Morpheus; Compumedics, Melbourne, Australia | PSG + PM at sleep lab |
Danzi-Soares et al[58] | 2011 | CAD patients | 79 | Stardust II, Respironics Inc., Murrysville, Pennsylvania, United States | PSG + PM at sleep lab |
Oliveira et al[68] | 2012 | COPD patients | 72 | Stardust II® (Phillips Respironics, Inc., Murrysville, PA, United States) | PSG + PM at sleep lab PM at home |
Lesser et al[78] | 2012 | Obese pediatric patients (9-18 yr ) | 25 | ApneaLink Plus (PesMed Corporation, Poway, CA) | PSG + PM at sleep lab |
Fredheim et al[79] (abstract) | 2014 | Morbidly obese patients | 105 | ApneaLink | PM PM + Embletta |
Oliveira et al[80] | 2014 | Obese patients | 58 | Stardust II® (Phillips Respironics, Inc., Murrysville, PA, United States) | PSG + PM at sleep lab PM at home |
- Citation: Treptow E, Oliveira MG, Moreira GA, Togeiro S, Nery LE, Tufik S, Bittencourt L. Update on the use of portable monitoring system for the diagnosis of sleep apnea in specific population. World J Respirol 2015; 5(1): 17-27
- URL: https://www.wjgnet.com/2218-6255/full/v5/i1/17.htm
- DOI: https://dx.doi.org/10.5320/wjr.v5.i1.17